Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pan-TEAD inhibitor ISM6331

An orally bioavailable non-covalent small molecule inhibitor of the TEA domain (TEAD) family of transcription factors, including TEAD1, TEAD2, TEAD3 and TEAD4, with potential antineoplastic activity. Upon oral administration, pan-TEAD inhibitor ISM6331 reversibly binds to the TEAD palmitoylation site and inhibits TEAD, thereby disrupting the interaction between the transcription co-activators yes-associated protein 1 (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) and TEAD. This may inhibit YAP/TAZ-TEAD-promoted transcription of multiple genes involved in tumor cell proliferation, progression and survival, and may result in enhanced apoptosis in TEAD-dependent cancers. Hippo pathway alterations, as seen in tumors with neurofibromatosis type 2 (NF2)-deficiency, large tumor suppressor 1 (LATS1) and 2 (LATS2) mutations and YAP/TAZ fusions, lead to Hippo pathway activation, hyperactivation of YAP/TAZ and activation of TEAD. It plays a key role in cancer initiation, progression, and cancer cell resistance to various therapies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:TEAD inhibitor ISM6331
Code name:ISM 6331
ISM-6331
ISM6331
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search